Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 5/20 | 0.61 |
| ▸ | ERCC4 | Q92889 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | GALR3 | O60755 | 1/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25252399 | 0.84 | TSHR (0.47) | ERCC1ERCC4KMT2ANPC1RAB9A | |
| SCHEMBL4247795 | 0.83 | ERCC1 (0.56) | ERCC1ERCC4KMT2ANPC1RAB9A | |
| SCHEMBL9393209 | 0.83 | KDM4E (0.49) | ERCC1ERCC4KMT2AP2RX7HPGD | |
| SCHEMBL8744740 | 0.82 | ERCC1 (0.59) | ERCC1ERCC4KMT2ANPC1RAB9A | |
| SCHEMBL8744815 | 0.81 | GAA (0.56) | ERCC1ERCC4KMT2ANPC1RAB9A | |
| SCHEMBL6136388 | 0.80 | ERCC1 (0.48) | ERCC1ERCC4KMT2AP2RX7HPGD | |
| SCHEMBL17914676 | 0.80 | ALDH1A1 (0.62) | ERCC1ERCC4NPC1RAB9AP2RX7 | |
| SCHEMBL8204517 | 0.80 | ERCC1 (0.54) | ERCC1ERCC4KMT2ANPC1RAB9A | |
| SCHEMBL9523440 | 0.79 | ALDH1A1 (0.65) | ERCC1ERCC4KMT2ANPC1RAB9A | |
| SCHEMBL30545006 | 0.79 | ALDH1A1 (0.65) | ERCC1ERCC4KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7335725-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | CLPTM1, NGLY1, VIP | ERCC1 3679/4885ERCC4 1687/4885KMT2A 4561/4885 |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | ERCC1 3679/4885ERCC4 1687/4885KMT2A 4561/4885 |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | ERCC1 3679/4885ERCC4 1687/4885KMT2A 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.